Synfini
Category: AI in Biotech / Drug Discovery
An AI-driven drug discovery platform that integrates both physical and virtual chemistry processes to accelerate the creation of small molecule drugs. Synfini was founded in 2023. The company is led by Doug Donzelli. Based in Menlo Park, California. Team size: 10-50. Total funding raised: $53 million (comprised of over $40M in non-dilutive SRI development grants and subsequent venture investment). Latest round: $8.9 Million Expansion. Key investors include JSL Health Capital, SRI Ventures, WERU Investments, Ferocity Capital.
- Founded
- 2023
- Headquarters
- Menlo Park, California
- Team size
- 10-50
- Total funding
- $53 million (comprised of over $40M in non-dilutive SRI development grants and subsequent venture investment)
Value proposition
Significantly accelerates the drug discovery process by unifying target selection, compound design, and synthesis through an integrated AI and robotics platform.
Products and solutions
AI Cloud Foundry
Unique value
The platform combines neuro-symbolic AI with robotic automation and extensive chemistry datasets to create a closed-loop system for drug discovery.
Target customer
Pharmaceutical and biotechnology companies and researchers.
Industries served
Healthcare, Pharmaceuticals, Biotechnology
Technology advantage
Provides a unified, end-to-end workflow from virtual design to physical synthesis, aiming to make drug discovery faster and more cost-effective.
How they differentiate
Synfini differentiates by offering an integrated end-to-end platform that combines AI-driven design with robotic automation for physical chemical synthesis, whereas competitors may focus on specific parts of the discovery workflow like virtual screening or medicinal chemistry.
Main competitors
Atomwise, PostEra, Enveda Biosciences
Key partnerships
SRI International, Multispan, O2nix Bio
Notable customers
Multispan, O2nix Bio
Major milestones
Spun out of SRI International in 2023 with a platform built on over $40M in non-dilutive R&D. Established strategic collaborations with Multispan and O2nix Bio to co-discover and develop novel drug candidates. Closed an $8.9 million expansion funding round in July 2024 to scale its AI Cloud Foundry.
Growth metrics
Secured strategic collaborations with Multispan and O2nix Bio. Successfully closed an $8.9 million expansion round in July 2024 to scale operations and team.
Market positioning
An emerging leader in the AI-driven drug discovery space, backed by significant funding and spun out of SRI International.
Geographic focus
North America
Patents and IP
The company's platform is built on patented automated chemical synthesis technologies developed at and transferred from SRI International.
About Doug Donzelli
Doug Donzelli is a seasoned entrepreneur and executive with over 25 years of experience in founding and managing technology ventures. He has a strong background in computer science and has held leadership positions in several early-stage and growth-phase companies. His expertise lies in taking innovative technologies to market, particularly in the biotech and software sectors. As the CEO of Synfini, he is leading the company's mission to revolutionize drug discovery through their AI-driven platform.
Official website: https://synfini.com